SomaGen Posts $8.76 Million in Q1 Sales, Achieving Highest First-Quarter Results Since Founding

SomaGen, a U.S.-based multi-omics analytics company, recorded consolidated sales of $8.76 million in the first quarter of this year, marking the highest first-quarter results since the company's founding.

According to SomaGen's first-quarter report disclosed on the 13th, consolidated sales amounted to $8.76 million (approximately KRW 12.8 billion). This represents a 12.4% increase from $7.79 million in the same period last year, and is the highest first-quarter sales figure not only since its listing on KOSDAQ in 2020 but also in the company's history.

The improvement in profitability was also notable. The company's consolidated gross profit for the first quarter reached $2.11 million (about KRW 3.1 billion), a sharp increase of 48.8% from $1.42 million in the same period last year. During the same period, operating loss decreased to $480,000 (approximately KRW 700 million), down more than 61% from the $1.26 million loss recorded in the first quarter of the previous year.

On a separate basis, the company is assessed to have effectively reached its break-even point (BEP). SomaGen's first-quarter standalone sales amounted to $8.1 million (about KRW 11.9 billion), while operating loss was limited to $28,000 (about KRW 40 million). This represents a reduction in operating loss of approximately 97% compared to the $940,000 loss in the same period last year. The company explained that this is the lowest level of operating loss since its listing.

SomaGen analyzed that its improved performance was mainly driven by expanding its market share in the U.S. genomics analysis sector and restructuring its revenue portfolio to focus on high value-added services. In addition, the company explained that operational efficiency strategies contributed to simultaneous top-line growth and profitability improvement.

The company's financial stability has also been reinforced. As of the end of the first quarter this year, consolidated cash and cash equivalents stood at $6.69 million (about KRW 1.01 billion). In particular, the company emphasized that it has been operating its business based on self-generated cash flow since its KOSDAQ listing in 2020, without relying on additional external funding.

A SomaGen official stated, "This performance demonstrates that the growth strategies pursued since our listing have produced tangible results, leading to a record-high first-quarter performance. With standalone operating profit reaching break-even, we plan to continue aggressive sales and profit-centered management for the remainder of the year, making it highly likely that we will achieve annual operating profit again this year, just as we did last year."

This performance is evaluated as evidence that SomaGen has entered a full-fledged turnaround phase, achieving both top-line growth and profitability improvement simultaneously.

This content was produced with the assistance of AI translation services.